Adding either of two new drugs — VX-659 or VX-445 — to the standard tezacaftor-ivacaftor combination improves both lung function and sweat chloride concentrations in most patients with cystic fibrosis ...
CAMBRIDGE, MA--(Marketwired - Nov 20, 2015) - Proteostasis Therapeutics, Inc. (PTI), a company developing small molecule therapeutics to treat diseases caused by defects in protein processing, ...
Challenged urine bicarbonate excretion provided a simple and safe quantification of cystic fibrosis transmembrane conductance regulator function among adults with cystic fibrosis, according to data ...
BOSTON, Mass., Nov. 3, 2022 /PRNewswire/ -- Sionna Therapeutics, a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today ...
Elexacaftor-tezacaftor-ivacaftor (ETI) may improve bronchial dilatations in adolescents with cystic fibrosis (CF).
Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.
Detailed price information for Sionna Therapeutics Inc (SION-Q) from The Globe and Mail including charting and trades.
Please provide your email address to receive an email when new articles are posted on . “[These findings] help clinicians be more supportive of a female with CF becoming pregnant,” Raksha Jain, MD, ...
Live webcasts of the presentations will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. Replays will also be available ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback